More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...

Development of B cells, white blood cells that make antibodies, follows a progression of stages: common lymphoid progenitors, pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and then more ...

Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...

Please provide your email address to receive an email when new articles are posted on . 40% of responders remained in remission without subsequent stem cell transplantation or other therapy. Ongoing ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial. The Food and Drug Administration (FDA) ...

Researchers from the School of Veterinary Medicine and Perelman School of Medicine have found that YY1 knockout pro-B cells can generate T lineage cells helping B cells produce antibodies. Development ...